Repligen (NASDAQ:RGEN) Given New $200.00 Price Target at JPMorgan Chase & Co.
Repligen (NASDAQ:RGEN – Get Free Report) had its target price boosted by equities research analysts at JPMorgan Chase & Co.
Repligen (NASDAQ:RGEN) Price Target Raised to $170.00 at Canaccord Genuity Group
Repligen (NASDAQ:RGEN – Get Free Report) had its target price increased by analysts at Canaccord Genuity Group from $165.00 ...
Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook
Repligen Corp (NASDAQ:RGEN) released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago ...
Repligen Corp (RGEN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Repligen Corp (RGEN) reports robust fourth-quarter revenue growth, driven by product differentiation and strategic ...
Repligen's Q4 Slightly Tops Expectations
In the fourth quarter, Repligen's performance was mixed. Adjusted earnings per share (EPS) surpassed analysts' expectations ...
Hosted on MSN3d
Repligen (NASDAQ:RGEN) Posts Q4 Sales In Line With Estimates
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) in Q4 CY2024, but sales were flat year on year at $167.5 ...
Repligen outlines 10-14% non-COVID revenue growth for 2025 driven by CDMO and equipment traction
Q4 2024 Management View CEO Olivier Loeillot highlighted that Repligen achieved Q4 2024 revenue of $167.5 million and full-year revenue of $634.4 million, meeting the midpoint of their November ...
Repligen price target raised to $170 from $165 at Canaccord
Canaccord raised the firm’s price target on Repligen (RGEN) to $170 from $165 and keeps a Buy rating on the shares. The firm said they reported ...
Repligen (RGEN) Receives a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Repligen (RGEN – Research Report) today and set a price target of $207.00. The ...
Jefferies上调Repligen目标价至165美元，维持持有评级
周四，Jefferies将Repligen Corporation（NASDAQ:RGEN）的目标价从160.00美元上调至165.00美元，同时维持对该股的持有评级。该公司股票目前交易价格为164.19美元，过去一年回报率为-24.53%。此次调整是在该公司同行Sartorius发布财报后，Repligen股价下跌约15%的背景下做出的。根据 InvestingPro ...
Repligen's Q4 Earnings Beat Estimates, Revenues In Line
More on RGEN's Q4 Earnings. Product revenues (including revenues from base business) were $167.4 million, up 0.
H.C. Wainwright维持Repligen买入评级，目标价180美元
周五，H.C. Wainwright分析师重申对Repligen Corporation（NASDAQ:RGEN）的买入评级和180.00美元的目标价。这一评级确认是在Repligen最近公布2024年第四季度和全年财务业绩，以及提供2025年财务展望之后作出的。该股近期表现强劲，过去一周上涨超过10%，尽管 InvestingPro ...